Rabbit anti‐thymocyte globulin administration to treat rejection in simultaneous pancreas and kidney transplant recipients with recent COVID‐19 infection
dc.contributor.author | Barros, Nicolas | |
dc.contributor.author | Sharfuddin, Asif A. | |
dc.contributor.author | Powelson, John | |
dc.contributor.author | Yaqub, Muhammad | |
dc.contributor.author | Adebiyi, Oluwafisayo O. | |
dc.contributor.author | Beeler, Cole | |
dc.contributor.author | Lutz, Andrew | |
dc.contributor.author | Fridell, Jonathan A. | |
dc.contributor.department | Medicine, School of Medicine | en_US |
dc.date.accessioned | 2021-01-15T22:11:51Z | |
dc.date.available | 2021-01-15T22:11:51Z | |
dc.date.issued | 2020 | |
dc.description.abstract | Transplant recipients may be more susceptible to COVID‐19 and itsrelated complications.1‐3Despite most patients being managed with reduction of immunosuppression, the risk of rejection or graft loss does not seem to be increased during COVID‐19. | en_US |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | Barros, N., Sharfuddin, A. A., Powelson, J., Yaqub, M., Adebiyi, O. O., Beeler, C., ... & Fridell, J. A. (2020). Rabbit anti‐thymocyte globulin administration to treat rejection in simultaneous pancreas and kidney transplant recipients with recent COVID‐19 infection. Clinical transplantation, e14149. https://doi.org/10.1111/ctr.14149 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/24875 | |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.relation.isversionof | 10.1111/ctr.14149 | en_US |
dc.relation.journal | Clinical Transplantation | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | Author | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | transplant recipients | en_US |
dc.subject | rabbit anti-thymocyte globulin | en_US |
dc.title | Rabbit anti‐thymocyte globulin administration to treat rejection in simultaneous pancreas and kidney transplant recipients with recent COVID‐19 infection | en_US |
dc.type | Article | en_US |